Q-omics provides the consensus-scored RPS5 profile across patient tissues and cancer cell-line models. RPS5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS5 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RPS5 protein abundance shows 29,174 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where RPS5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS5 survival associations across molecular data types. RPS5 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS5 RNA expression–survival associations across cancer types. High RPS5 expression shows unfavorable associations in ACC, LIHC, KIRP, STAD and SARC, but favorable associations in UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS5 RNA expression.
This table summarizes RPS5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RPS5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS5 shows lower tumor expression in BRCA and higher tumor expression in KIRC, COAD, KIRP, LIHC and LUSC. The KIRC box plot shows higher RPS5 RNA expression in tumor versus normal tissue (log2 FC = +1.061, t-test p < 0.001).
This table shows molecular features associated with RPS5 in patient tissues and cancer cell lines. In patient samples, RPS5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
